

VLST Corp. Names Julie M. Eastland as Chief Financial Officer

Seattle (March 3, 2006) – VLST Corp., a Seattle-based biotechnology company, today announced the appointment of Julie M. Eastland as Chief Financial Officer.

Eastland joins VLST from Dendreon Corporation, where she held various finance positions, most recently as the vice president of strategic planning. Ms. Eastland joined Dendreon in 2000, where she held a variety of increasingly responsible financial positions. Prior to joining Dendreon, Ms. Eastland worked for Amgen, Inc. as area finance manager and assistant controller for its Colorado operations. Ms. Eastland also worked as controller for Biovail Technologies, international finance & business manager for *SCIENCE Magazine*, and financial manager for the Discovery Channel. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S., finance from Colorado State University.

“Julie brings a wealth of industry related financial experience gained at leading biotech firms such as Amgen to VLST. This experience will be invaluable as we continue to capitalize and advance VLST,” said Martin A. Simonetti, president and chief executive officer of VLST. “Her background will serve VLST well as we emerge from the Accelerator and move into our own facilities and develop our infrastructure. We are very pleased to welcome Julie to the VLST management team.”

“I am pleased to be joining the VLST team at this exciting time in the company’s development. I look forward to making significant contributions to the development of therapeutics for chronic inflammatory and autoimmune disorders.” said Ms. Eastland.

About VLST

VLST Corp. is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. This approach combines cutting-edge bioinformatics and proteomics with in-depth understanding of key inflammatory processes to provide a rapid and rational approach to the development of novel therapies. Such an approach offers the opportunity to speed up the introduction of new drugs by saving considerable time and development expenses upfront. The Company’s technology has potential applications for the treatment of multiple sclerosis, lupus, rheumatoid arthritis and diabetes. VLST was launched in May 2004 as one of the first start-ups to join Accelerator Corporation, an investment vehicle supporting the formation and development of next-generation biotechnology companies. For more information, visit www.vlstcorp.com.

###